Millions across Africa to gain access to weight-loss and diabetes drugs as Aspen ramps dis

JOHANNESBURG. Hundreds of millions of people across sub-Saharan Africa stand to gain broader access to weight-loss and diabetes treatments as Aspen Pharmacare accelerates its distribution of Eli Lilly’s Mounjaro, with the South African company now projecting sales exceeding 2 billion rand, or $124 million, in its financial year ending June 2027.

The scale of patient uptake in South Africa already signals how acute the need is. The country’s market for GLP-1 receptor agonist drugs nearly doubled in value to 2.8 billion rand over the past year. Mounjaro, launched in late 2024, captured more than half of all sales in that period, with its market share jumping from 15% to 53%. That pace of adoption reflects not just commercial momentum but a population actively seeking treatment for obesity and diabetes, conditions that carry serious long-term health consequences.

What changed the picture further is where Aspen is heading next. The company has already submitted Mounjaro for regulatory approval in Kenya and Nigeria, two of Africa’s most populous nations. If those registrations proceed, both markets could begin contributing to patient access within the current financial year, extending treatment options to hundreds of millions of additional people across the continent.

Chief Executive Stephen Saad outlined the expansion strategy in remarks to investors the day after releasing annual results. The 2027 forecast of more than 2 billion rand represents a substantial increase from his earlier estimate of over 1.3 billion rand for the year ending June 2026, though Aspen has not publicly disclosed actual sales figures for that prior period. The acceleration underscores how quickly demand for these medications is taking hold, and how Aspen’s role as Lilly’s official distributor positions it to meet that demand at scale.

Meanwhile, Aspen is pursuing a parallel path that carries significant implications for affordability. The company has secured two product registrations in Canada for a generic version of Novo Nordisk’s Ozempic and has filed applications across several emerging markets. Once patent protections expire, this approach could offer patients and public health systems lower-cost alternatives, a critical consideration in price-sensitive markets where healthcare budgets are already stretched thin by rising rates of obesity and diabetes.

Supply chain complications, however, create near-term uncertainty for patients waiting on those generics. Aspen’s commercial launch of its generic Ozempic in Canada depends on the active pharmaceutical ingredient supplied by Dr. Reddy’s Laboratories in India. That supplier halted production of new batches in July due to an impurity issue, leaving the timing of Aspen’s market entry unclear. Saad indicated the company expected clearer visibility on the supply arrangement before the end of the month.

To reduce that risk, Aspen is engaging a different API supplier for its planned launch in Brazil, where registration progress is also advancing. The move reflects a broader reality of pharmaceutical manufacturing across emerging markets: securing reliable ingredient sources is as consequential for public health outcomes as regulatory approval itself. Delays at any point in that chain translate directly into delayed access for patients.

For African healthcare systems navigating budget constraints while confronting a growing burden of chronic disease, the trajectory Aspen is charting raises a question that will matter well beyond any single financial year: whether the eventual arrival of lower-cost generics will come quickly enough, and at prices accessible enough, to reach the patients who need them most.